TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...
Dublin, May 11, 2026 (GLOBE NEWSWIRE)-- The "Lecanemab Injection Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Lecanemab Injection Market Global Report 2026 serves as a ...
--Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration has approved the Biologics License Application for once weekly lecanemab-irmb subcutaneous injection for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...
(MENAFN- GlobeNewsWire - Nasdaq) The lecanemab injection market offers key opportunities due to increased early-stage Alzheimer's diagnosis, rising global aging, and expansion in reimbursement.
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters ...
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results